Bausch & Lomb optimistic on FDA approval for laser
This article was originally published in Clinica
The share price of eye healthcare company Bausch & Lomb rose by nearly 8% last week on the announcement that the company was "highly confident" that the US FDA would waive a panel review of its pre-market approval application by the ophthalmic devices panel for its laser for LASIK refractive surgery procedures.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.